Pharmazz, Inc., ReAlta Life Sciences, Acer Therapeutics, expected to drive market
The Asphyxia market growth is driven by factors like increase in the prevalence of Asphyxia, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Asphyxia market report also offers comprehensive insights into the Asphyxia market size, share, Asphyxia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Asphyxia market size growth forward.
Some of the key highlights from the Asphyxia Market Insights Report:
Several key pharmaceutical companies, including Pharmazz, Inc., ReAlta Life Sciences, Acer Therapeutics, and others, are developing novel products to improve the Asphyxia treatment outlook.
In December 2024, the U.S. Food and Drug Administration approved Zepbound for treating moderate to severe OSA in adults with obesity. Zepbound functions by activating receptors of intestinal hormones to reduce appetite and food intake, leading to weight loss and improvement in OSA symptoms. Clinical trials demonstrated a significant reduction in apnea and hypopnea events among participants treated with Zepbound compared to placebo.
A Phase I clinical study conducted at the Montreal Children's Hospital explored the use of sildenafil, commonly known as Viagra, to treat newborns suffering from neonatal encephalopathy due to oxygen deprivation during birth. The study found that sildenafil administration is feasible and safe, showing encouraging signs of efficacy in repairing brain injury caused by birth asphyxia. Further research is ongoing to confirm these findings and establish optimal dosing.
Recent developments in clinical trials for asphyxia have demonstrated significant progress in addressing this critical condition. On August 2, 2023, ReAlta Life Sciences launched a Phase II trial to assess the safety, tolerability, pharmacokinetics, and preliminary effectiveness of RLS-0071 in newborns with hypoxic-ischemic encephalopathy (HIE), also known as birth asphyxia. This randomized, double-blind, placebo-controlled study follows a two-stage, multiple-ascending dose design to explore potential treatments for affected newborns.
Additionally, a randomized clinical trial conducted by the HEAL Consortium and published in the *New England Journal of Medicine* on January 12, 2022, examined the use of erythropoietin in treating HIE. The study aimed to improve outcomes for infants with birth asphyxia, providing crucial insights for future therapeutic approaches. These advancements highlight ongoing efforts to enhance the understanding and management of asphyxia, ultimately working toward better patient outcomes.
As per DelveInsight analysis, the Asphyxia market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Asphyxia Market Landscape
Asphyxia Overview
Asphyxia is a condition caused by insufficient oxygen supply, which can lead to organ failure and life-threatening complications. It can result from airway obstruction, drowning, suffocation, or exposure to toxic gases, triggering symptoms such as rapid heart rate, confusion, and loss of consciousness.
There are three main types of asphyxia:
- Mechanical Asphyxia – Caused by airway obstruction or external pressure on the chest.
- Chemical Asphyxia – Results from inhaling toxic substances like carbon monoxide or cyanide, which prevent oxygen utilization.
- Environmental Asphyxia – Occurs in low-oxygen environments, such as confined spaces or high altitudes.
Common symptoms include breathing difficulties, cyanosis (bluish skin), and, in severe cases, unconsciousness or death. Immediate treatment is essential and may involve clearing the airway, providing oxygen, or performing CPR. Early intervention and awareness are crucial in preventing severe outcomes.
Do you know the treatment paradigms for different countries? Download our Asphyxia Market Sample Report
Asphyxia Epidemiology Insights
Asphyxia, a condition caused by insufficient oxygen supply, affects individuals across various age groups and settings. It is a significant global health concern, particularly in newborns and adults exposed to environmental or occupational hazards.
Birth asphyxia affects approximately 2 to 3 per 1,000 live births in high-income countries but is significantly higher in low- and middle-income regions, where it contributes to one-quarter of all neonatal deaths.
Asphyxia Epidemiology Segmentation
DelveInsight's Asphyxia market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Asphyxia historical patient pools and forecasted Asphyxia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Asphyxia Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Asphyxia Prevalence
Age-Specific Asphyxia Prevalence
Gender-Specific Asphyxia Prevalence
Diagnosed and Treatable Cases of Asphyxia
Visit for more @ Asphyxia Epidemiological Insights
Asphyxia Market Outlook
The market for asphyxia-related treatments, particularly focusing on neonatal asphyxia or asphyxia neonatorum, is projected to experience significant growth in the coming years.
The asphyxia market growth is largely attributed to advancements in neuroprotective therapies, including the development of novel therapeutic agents such as neuroprotective drugs, surfactants, and anti-inflammatory agents. These innovations aim to more effectively address the pathophysiology of neonatal asphyxia, targeting critical issues like neuroinflammation and oxygen deprivation-induced brain injury.
Asphyxia Key Companies
Pharmazz, Inc., ReAlta Life Sciences, Acer Therapeutics, and others
For more information, visit Asphyxia Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Asphyxia Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Asphyxia, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Asphyxia epidemiology in the 7MM
Asphyxia marketed and emerging therapies
Asphyxia companies
Asphyxia market drivers and barriers
Table of Contents:
1 Asphyxia Market Key Comprehensive Insights
2 Asphyxia Market Report Introduction
3 Competitive Intelligence Analysis for Asphyxia
4 Asphyxia Market Analysis Overview at a Glance
5 Executive Summary of Asphyxia
6 Asphyxia Epidemiology and Market Methodology
7 Asphyxia Epidemiology and Patient Population
8 Asphyxia Patient Journey
9 Asphyxia Treatment Algorithm, Asphyxia Current Treatment, and Medical Practices
10 Key Endpoints in Asphyxia Clinical Trials
11 Asphyxia Marketed Therapies
12 Asphyxia Emerging Therapies
13 Asphyxia: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Asphyxia
16 Asphyxia Market Key Opinion Leaders Reviews
18 Asphyxia Market Drivers
19 Asphyxia Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Asphyxia Epidemiology 2032
DelveInsight's "Asphyxia - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Asphyxia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Asphyxia Pipeline 2024
"Asphyxia Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Asphyxia market. A detailed picture of the Asphyxia pipeline landscape is provided, which includes the disease overview and Asphyxia treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market share. However, Regeneron is constantly looking for its next billion-dollar medicine. And a recent deal it made with a smaller drugmaker helped it beef up its pipeline by acquiring an asset in the hottest therapeutic area right now: weight management. Is Regeneron stock a buy now? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Going up against a giant Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per the terms of the agreement, Regeneron will pay an upfront amount of $80 million, with potential clinical and regulatory milestones of up to $1.93 billion, in addition to royalties on future sales. HS-20094 mimics the action of two gut hormones: GLP-1 and GIP. The only approved medicine that does that is Zepbound, the weight loss therapy marketed by Eli Lilly. Zepbound has been a major hit, with incredibly fast-growing sales. Could HS-20094 become similarly successful? The fact that it's in the same class as Zepbound hardly guarantees so, but, according to Regeneron, the medicine has been tested in over 1,000 patients and has shown a potential similar to Zepbound. It is currently undergoing a Phase 3 clinical trial for obesity and a Phase 2 study for diabetes. Results that are, in fact, on par with Zepbound might jolt Regeneron's share price. This isn't the only attempt by Regeneron to enter the weight loss market. The biotech company has been working on ways to address one drawback of anti-obesity medicines: muscle loss. It recently announced top-line data in patients taking semaglutide (the active ingredient in the weight loss drug Wegovy) and trevogrumab, a medicine developed to address muscle atrophy. The trial showed that about 35% of weight loss due to semaglutide comes from lean muscle mass, but combining it with trevogrumab could help retain muscle mass while helping patients lose fat instead. Does this make Regeneron a buy? If HS-20094 becomes nearly as successful as Zepbound, the $80 million Regeneron paid -- and the $1.93 billion in milestones -- would represent quite the bargain. However, it is too early to celebrate. Despite Regeneron's confidence in this asset, many weight management candidates in the pharmaceutical industry have flopped. That's the nature of developing novel drugs. Most will never reach the market. But the fact that HS-20094 has reached late-stage studies is a good sign. And at any rate, this move does not make Regeneron less attractive. There are, however, other reasons to buy the stock. Regeneron is mitigating Eylea-related losses with a new, high-definition (HD) version of the medicine, which will continue to attract patients away from the old version due to its more convenient dosing schedule. In the first quarter, total U.S. sales of Eylea and Eylea HD dropped by 26% year over year to $1.04 billion, but revenue from the latter increased by 54% year over year to $307 million. Eylea HD should also earn some label expansions. Meanwhile, Regeneron's other growth driver is Dupixent, a medicine for eczema. It shares the rights to Dupixent with Sanofi. In the first quarter, Dupixent's sales came in at $3.67 billion, up 19% compared to the year-ago period. The therapy won an indication in treating COPD last year, so expect its revenue to continue moving in the right direction for a while. Regeneron's total sales in the first quarter dropped by 4% year over year to $3 billion. However, as Eylea HD gains ground, including with new indications, Dupixent continues to make headway, and the biotech earns new products, including those in oncology, it should eventually start growing its sales again. Regeneron's work in weight management could, eventually, contribute to that. So, despite its recent headwinds, the stock still looks attractive. Should you invest $1,000 in Regeneron Pharmaceuticals right now? Before you buy stock in Regeneron Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Cision Canada
3 days ago
- Cision Canada
Perimeter Medical Imaging AI to Present at the Life Sciences Virtual Investor Forum on June 12th
TORONTO and DALLAS, June 10, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its CEO, Adrian Mendes, will present an update on the Company's business at the Life Sciences Virtual Investor Forum on Thursday, June 12, 2025 at 12:30 p.m. Eastern Time. A live stream of the presentation will be available here and on the Investors section of Perimeter's website, where it will also be archived for approximately 90 days. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was recently evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT, the expected benefits of Perimeter's updated version of its ImgAssist AI, and Perimeter's expectations regarding the outcomes of the clinical trial and future submission to the FDA are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2023, which is available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. Stephen Kilmer Investor Relations Direct: 647-872-4849 Email: [email protected] Adrian Mendes Chief Executive Officer Toll-free: 888-988-7465 (PINK) Email: [email protected]
Cision Canada
3 days ago
- Cision Canada
Smart Healthcare Is Taking Over. Here's Where the Money's Headed
VANCOUVER, BC, June 10, 2025 /CNW/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI tools. But as implementations increase across the sector, so too are major developments coming from innovators, including Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL), Omada Health, Inc. (NASDAQ: OMDA), and Inc. (NASDAQ: AMZN). McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. Statista now projects the global AI healthcare market will soar from $11 billion to $188 billion by 2030. Avant Technologies, Inc. (OTCQB: AVAI) has just taken a major step forward in its evolution from AI incubator to full-stack healthcare innovator. Today, the company announced it had signed a non-binding letter of intent to acquire 100% of Ainnova Tech, its joint venture partner and the developer of the Vision AI diagnostic platform. Prior to the acquisition, the two companies have been operating jointly through Ai-nova Acquisition Corp (AAC), which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments. "We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of AAC. "We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare." Under the proposed agreement, Ainnova would roll all of its outstanding equity into the combined public entity — unifying leadership and eliminating structural complexity ahead of a scheduled FDA pre-submission meeting in July. While final terms of the deal are still being negotiated, both companies say the merger would streamline commercialization and accelerate the rollout of Ainnova's flagship Vision AI technology — a platform already in use across clinical sites in Latin America for the early detection of diabetic retinopathy, cardiovascular disease, and other chronic conditions. The move also signals growing confidence from Avant's leadership as they prepare to bring proprietary hardware into the mix. In parallel with the merger discussions, Avant and Ainnova are entering the final prototyping stage of a low-cost, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics. The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel. The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics. "The cost of a fundus camera has always been a barrier to entry in this market," said Vargas. "Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market." Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare. "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care. Renovaro Inc. (NASDAQ: RENB) recently announced a major expansion to its intellectual property portfolio with a newly approved U.S. patent for its AI-powered drug discovery and diagnostics infrastructure. "This patent is a strategic milestone for Renovaro," said David Weinstein, CEO of Renovaro. "Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights." The patent protects methods that harmonize genomic, imaging, clinical, and health record data into a standardized framework for large-scale predictive analytics. These capabilities are built for distributed computing environments, aligning with the biopharma industry's move toward real-time, scalable analytics. The development enhances Renovaro's competitive positioning in data-driven therapeutics and clinical insight markets. Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL) recently showcased its leadership in AI-driven cancer research at the 2025 ASCO Annual Meeting, where Ruth Porat discussed Alphabet's evolving role in early diagnosis and treatment. "AI has greater potential than the internet, because it can augment human capabilities," wrote Ruth Porat, President & Chief Investment Officer of Alphabet and Google, quoting Vint Cerf. "It is a partner for all of you, for each of us." Porat highlighted Google's success with AlphaFold, which has accelerated cancer drug discovery by solving the decades-long problem of protein folding. She also noted the company's AI-assisted pathology tools that cut diagnostic time in half and improve detection of small metastases. From scalable diabetic retinopathy screening to generative AI for clinical workflows, she framed AI as a transformative force in healthcare delivery. Omada Health, Inc. (NASDAQ: OMDA) entered the public markets with a strong debut, raising $150 million and closing its first trading day 21% above IPO pricing. The company delivers AI-augmented virtual care for chronic conditions like diabetes, hypertension, and obesity, serving more than 679,000 active members. In May, prior to the IPO, Omada introduced Nutritional Intelligence, a new member experience powered by OmadaSpark—an AI agent that offers personalized, evidence-based nutrition coaching between clinical visits. As demand rises for GLP-1 medications, Omada is positioning its human-plus-AI model as essential to long-term metabolic health. "We believe there is a clear market need for real-time educational support backed by behavioral science to improve mindsets and behaviors toward food," said Wei-Li Shao, President at Omada Health. "To meet the needs of our customers and members, Omada fine tuned its approach to offer AI-powered tools trained with clinical input and expertise to work alongside human care teams in helping members drive improved health and economic outcomes." Inc. (NASDAQ: AMZN) continues to scale its digital health footprint via Amazon Web Services (AWS), which recently brought its HealthLake platform to the EU's Dublin Region. The move enables hospitals and insurers to unify siloed patient data using FHIR standards, while running AI-driven analytics and maintaining full data residency compliance. "I'm excited about AWS HealthLake launch in EU Region," said Ramon Postulart, CTO at Adapcare. " AWS HealthLake is a key AWS healthcare service helping us modernize interoperability across the 70+ care organizations and 60,000 health professionals we support in the Netherlands. By moving to this service, we're unlocking richer, standardized health data and leveraging the HealthLake fully managed capabilities to build smarter, AI-powered tools for care planning and coordination." HealthLake now serves as the engine behind personalized care tools in development across Ireland, the Netherlands, and Finland. AWS also hosted its Health Data & AI Day in Dublin to promote cross-border health data innovation and the European Health Data Space initiative. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
